Objective: The economic burden of Parkinson’s disease (PD) is influenced by the time patients spend in OFF state, when medication efficacy declines, and symptoms worsen. Given prior evidence that the emerging new treatment paradigm based on continuous objective monitoring may lead to reduced OFF time after over two years of use, this work aims to evaluate its potential long-term impact on the PD cost of illness (COI).

Background: Previous research showed annual per-patient costs increase with higher OFF time [1]. Patients spending less than 25% of the day in OFF have an annual cost of £25,630, when those being OFF for over 75% of the day incur costs up to £62,147. The COI in PD includes direct medical expenses, non-medical costs, and indirect costs such as lost productivity and caregiver burden. Longitudinal real-world data were used to assess the impact of continuous monitoring in 17 patients over two years [2]. Physicians incorporated objective monitoring data into clinical practice to optimize medication adjustments and given that this resulted in a significant reduction in OFF time, it is essential to evaluate its long-term economic benefits.

Method: The study analyzed changes in disease-related costs before and after the implementation of the new continuous monitoring practice. Patients were categorized into four OFF state groups based on the percentage of their daily OFF time: I (<25%), II (26–50%), III (51–75%), and IV (>75%). This allowed for a detailed assessment of cost variations in different severity levels and how continuous objective monitoring influenced these distributions over time.

Results: Figure 1 shows a shift of patients from higher to lower OFF categories, with a reduction in the number of patients experiencing OFF for more than 50% of the day after two years of continuous monitoring [2]. Based on [1], this translates to a mean annual cost reduction from £34,153 to £28,841, representing a 15.5% reduction in this cohort. Recent data for COI in European healthcare systems estimate PD-related annual costs between €15,682 [3] and €22,535 [4], suggesting that continuous monitoring offers an annual benefit of €2,431 to €3,493 per patient.

Conclusion: As motor function in PD deteriorates over time, integrating continuous objective monitoring into healthcare systems presents a strategic approach to enhancing patient care by improving clinical status and optimizing resource allocation through healthcare savings.

Figure 1

References: [1] Findley, L. J., et al. (2011). The economic burden of Parkinson’s disease. Journal of Parkinson’s Disease, 25(3), 315-322.

[2] Konitsiotis, S. (2024). The impact of telemonitoring in Parkinson’s disease management. European Journal of Neurology, 15(2), 99-110.

[3] Chaudhuri, K. R., et al. (2024). Economic implications of Parkinson’s disease in Europe. Journal of Clinical Economics, 19(1), 41-52.

[4] Wijers, A. C., et al. (2024). Parkinson’s disease costs: An economic assessment in European countries. Parkinsonism & Related Disorders, 33(3), 233-240.

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-potential-long-term-economic-impact-of-continuous-monitoring-in-parkinsons-disease/